SCN1B and Dravet syndrome: Treatment with the NKCC1 antagonist bumetanide prolongs the lifespan of a subset of Scn1b−/− mice, suggesting that therapeutic strategies targeting GABAergic signaling polarity may be useful in reducing SUDEP risk in DS.